{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:59Z","timestamp":1777509419168,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.amjcard.2009.10.001","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T04:34:44Z","timestamp":1258173284000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-Term Safety and Efficacy of Triple Combination Ezetimibe\/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia"],"prefix":"10.1016","volume":"105","clinical-trial-number":[{"clinical-trial-number":"nct00271817","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sergio","family":"Fazio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam B.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeniyi J.","family":"Adewale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.10.001_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.10.001_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.10.001_bib3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1517\/14656566.8.11.1711","article-title":"Present-day uses of niacin: effects on lipid and non-lipid parameters","author":"Sanyal","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjcard.2009.10.001_bib4","series-title":"Niaspan [product insert]","year":"2008"},{"key":"10.1016\/j.amjcard.2009.10.001_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.001_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary-artery disease as a result of intensive lipid-lowering therapy in men with high-levels of apolipoprotein-B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.10.001_bib7","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.10.001_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2009.10.001_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.10.001_bib10","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2\u2014a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.10.001_bib11","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib12","series-title":"Vytorin [Product Insert]","year":"2009"},{"key":"10.1016\/j.amjcard.2009.10.001_bib13","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2009.10.001_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin versus atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2009.10.001_bib15","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus Rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2009.10.001_bib16","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease\u2014the ADMIT study: a randomized trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.10.001_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP44633","article-title":"Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation","volume":"44","author":"Cefali","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2009.10.001_bib23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc09-S013","article-title":"Standards of medical care in diabetes-2009","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2009.10.001_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1185\/030079905X43677","article-title":"Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel","volume":"21","author":"Shepherd","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2009.10.001_bib25","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes\u2014results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2009.10.001_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atheroscleorsis"},{"key":"10.1016\/j.amjcard.2009.10.001_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended\/release\/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.10.001_bib29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima\u2013media thickness: ARBITER3*","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291490902476X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291490902476X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:00:59Z","timestamp":1762077659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291490902476X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S000291490902476X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.10.001","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Safety and Efficacy of Triple Combination Ezetimibe\/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}